Touching Base Drugs from a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge
Apr 9, 2026
Fay Lin, an AI-in-biology reporter, explains agentic AI, LabOS, and autonomous lab systems. Alex Philippidis, a biotech business editor, covers recent M&A and the heated obesity drug market. They discuss AI designing antibodies from text prompts, XR-guided experiments, major acquisitions reshaping pipelines, and how Novo Nordisk’s Wegovy pill heats up price and sales competition.
AI Snips
Chapters
Transcript
Episode notes
Text Prompts Can Produce Lab‑Validated Therapeutics
- AI agents are enabling end-to-end drug design from a simple text prompt to lab-validated binders.
- Latent Labs' Latent Y produced single-digit nanomolar nanobodies and ran campaigns ~56x faster, including designs from scientific papers targeting transferrin receptor for BBB crossing.
Extended Reality Bridges AI And The Physical Lab
- Extended reality platforms are connecting AI agents, smart glasses, and robots to guide physical experiments in real time.
- LabOS paired with CRISPR‑GPT showed how computational reasoning plus smart hardware can improve execution and reproducibility.
AI Aims To Fix Reproducibility Crisis
- Poor reproducibility is a major problem in biomedical research and AI agents aim to standardize execution and documentation.
- A Nature study found ~70% of scientists can't reproduce colleagues' experiments and platforms can enforce standardized protocols.